지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.1
- 수록면
- 48 - 55 (8page)
이용수
초록· 키워드
오류제보하기
Purpose: Data on the comparative effectiveness of infliximab (IFX) or adalimumab (ADA) in patients with ulcerative colitis (UC)are extremely limited, especially in the Asian population. We compared clinically important outcomes [colectomy, UC-relatedemergency room (ER) visits, UC-related hospitalizations, and need for corticosteroids] for these two biologics in biologic-naïveKorean patients with UC. Materials and Methods: Using National Health Insurance claims, we collected data on patients who were diagnosed with UC andexposed to IFX or ADA between 2010 and 2016. Results: A total of 862 new users of biologics were included, of whom 630 were treated with IFX and 232 were treated with ADA. Over a median follow-up of 1.8 years after starting biologic therapy, there were no significant differences in the risk of colectomy[adjusted hazard ratio (aHR), 1.87; 95% confidence interval (CI), 0.30–11.63], ER visits (aHR, 1.58; 95% CI, 0.79–3.16), hospitalizations(aHR, 0.83; 95% CI, 0.59–1.17), and corticosteroid use (aHR, 1.16; 95% CI, 0.76–1.78) between IFX and ADA users. These resultswere stable even when only patients who used biologics for ≥6 months were analyzed. Additionally, these results were unchangedin patients treated with biologic monotherapy or combination therapy with immunomodulators. Conclusion: In this nationwide population-based study, there was no significant difference in the risk of colectomy, ER visits, hospitalizations,and corticosteroid use between IFX and ADA users. Our findings indicate that IFX and ADA have comparable effectivenessin biologic-naïve Korean patients with UC.
목차
등록된 정보가 없습니다.
참고문헌 (0)
참고문헌 신청함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Comparison of Long-term Outcomes of Infliximab versus Adalimumab in 1,488 Biologic-Naive Korean Patients with Crohn’s Disease
Gut and Liver
2021 .01
-
Long-Term Durability of Infliximab for Pediatric Ulcerative Colitis: A Retrospective Data Review in a Tertiary Children's Hospital in Japan
Pediatric Gastroenterology, Hepatology & Nutrition
2021 .01
-
Long-Term Efficacy of Anti-Tumor Necrosis Factor Agents in Pediatric Luminal Crohn’s Disease: A Systematic Review of Real-World Evidence Studies
Pediatric Gastroenterology, Hepatology & Nutrition
2020 .01
-
Short-Term Outcome of Infliximab Therapy in Pediatric Crohn’s Disease: A Single-Center Experience
Pediatric Gastroenterology, Hepatology & Nutrition
2017 .01
-
Clinical Use of Measuring Trough Levels and Antibodies against Infliximab in Patients with Pediatric Inflammatory Bowel Disease
Gut and Liver
2017 .01
-
Factors Associated with the Immunogenicity of Anti-Tumor Necrosis Factor Agents in Pediatric Patients with Inflammatory Bowel Disease
Gut and Liver
2021 .01
-
Korean clinical practice guidelines on biologics and small molecules for moderate-to-severe ulcerative colitis
Intestinal research
2023 .01
-
Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018
Intestinal research
2021 .01
-
Is there a correlation between infliximab trough levels and the development of adverse events in patients with inflammatory bowel disease?
Intestinal research
2021 .10
-
Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naive Patients with Ulcerative Colitis
Gut and Liver
2021 .01
-
Pregnancy Outcomes Associated With Biologic Agent Exposure in Patients With Several Rheumatic Diseases and Inflammatory Bowel Diseases
Journal of Korean Medical Science
2023 .06
-
건선의 생물학제제 교체치료
대한건선학회지
2018 .01
-
Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study
Intestinal research
2022 .01
-
Infliximab Therapy for Children with Moderate to Severe Ulcerative Colitis: A Step-Up versus a Top-Down Strategy
Yonsei Medical Journal
2021 .01
-
Which areas are still left in biologics responsive Korean patients with moderate to severe plaque psoriasis
Annals of Dermatology
2023 .02
-
Efficacy of biologic therapies for biologic-naïve Japanese patients with moderately to severely active ulcerative colitis: a network meta-analysis
Intestinal research
2021 .01
-
Use of Anti-TNF Alpha Blockers Can Reduce Operation Rate and Lead to Growth Gain in Pediatric Crohn's Disease
Pediatric Gastroenterology, Hepatology & Nutrition
2019 .01
-
Biologic mesh
대한외과학회 학술대회 초록집
2016 .11
-
Similar Clinical Outcomes of Early and Late Anti-TNF Initiation for Ulcerative Colitis: A Nationwide Population-Based Study
Yonsei Medical Journal
2020 .01
-
Patterns of Ulcerative Colitis Treatments and Factors Affecting the Prescribing of Systemic Corticosteroid using Health Insurance Claims Database
한국임상약학회지
2020 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0